Newron Therapeutics on Thursday earned approval from the Food and Drug Administration for its drug Xadago.
Xadago is intended to be used as an add-on treatment for patients with Parkinson's disease who are already taking a combination therapy of levodopa and carbidopa for the condition, yet still experiencing "off" episodes.
"Off episodes" occur when a patient's medication is not working properly, resulting in heightened Parkinson's symptoms like tremors or difficulty walking, according to the FDA.
"Xadago as an add-on to levodopa/carbidopa provided a significant reduction in off time and a significant increase in ON time without troublesome dyskinesia in [Parkinson's] patients experiencing motor fluctuations," Warren Olanow, MD, a professor of neurology and neuroscience at the Mount Sinai School of Medicine in New York City, said in a statement.
More articles on supply chain:
96% of older Americans want Medicare to negotiate drug costs: 4 survey findings
FDA granted 99% of applications for access to unapproved drugs in FY 2016
FDA warns of safety risks with Abbott's dissolving stent: 5 takeaways